Sofinnova Investments, Inc. Chemo Centryx, Inc. Transaction History

Sofinnova Investments, Inc.

$1.06 Billion
Q3 2024

Shares

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $967,296 - $1.73 Million	62,975 Added 10.98%	636,659 $15.8 Million
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $3.5 Million - $6.16 Million	-157,538 Reduced 21.54%	573,684 $14.4 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $3.92 Million - $8.65 Million	213,514 Added 41.24%	731,222 $26.6 Million
Q3 2021 Nov 15, 2021	BUY	$13.18 - $19.83 $686,295 - $1.03 Million	52,071 Added 11.18%	517,708 $8.85 Million
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $2.74 Million - $14.5 Million	285,638 Added 158.69%	465,637 $6.24 Million
Q1 2021 May 14, 2021	BUY	$49.53 - $68.4 $3.31 Million - $4.57 Million	66,786 Added 58.99%	179,999 $9.22 Million
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $1.51 Million - $2.08 Million	31,978 Added 39.36%	113,213 $7.01 Million
Q3 2020 Nov 13, 2020	SELL	$46.35 - $61.69 $726,814 - $967,360	-15,681 Reduced 16.18%	81,235 $4.45 Million
Q2 2020 Aug 13, 2020	BUY	$38.58 - $65.07 $1.17 Million - $1.97 Million	30,221 Added 45.31%	96,916 $5.58 Million
Q1 2020 May 13, 2020	SELL	$32.73 - $50.78 $10.2 Million - $15.8 Million	-310,249 Reduced 82.31%	66,695 $2.68 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $2.57 Million - $14.9 Million	376,944 New	376,944 $14.9 Million
Q3 2018 Nov 15, 2018	SELL	$10.49 - $13.72 $716,026 - $936,499	-68,258 Closed	0 $0
Q2 2018 Nov 15, 2018	BUY	$10.62 - $13.98 $724,899 - $954,246	68,258 New	68,258 $899,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sofinnova Investments, Inc. with notifications on news.